- Home
- LUCD vs SLGL Comparison
LUCD vs SLGL Comparison
Compare LUCD & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | SLGL |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 218.9M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LUCD | SLGL |
|---|---|---|
| Price | $0.64 | $71.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $4.00 | ★ $152.50 |
| AVG Volume (30 Days) | ★ 1.5M | 35.8K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $33.93 | N/A |
| Revenue Next Year | $165.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.50 | $28.81 |
| 52 Week High | $1.63 | $97.97 |
Technical Indicators
Market Signals| Indicator | LUCD | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 51.74 |
| Support Level | $0.50 | $69.09 |
| Resistance Level | $1.09 | $81.18 |
| Average True Range (ATR) | 0.07 | 4.60 |
| MACD | -0.01 | 0.93 |
| Stochastic Oscillator | 35.14 | 62.58 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.